Strides Pharma Science (Mid Cap - High Growth) Share Target 2024, 2025 To 2039
|
Strides Pharma Science Limited |
|||
|
Price: ₹682.30 | ||
| 52 Week Low: ₹566.10 52 Week High: ₹1,675.00 |
|||
| Market Capital: 8,018.81 Crore (Midcap) | |||
| Healthcare -> Drug Manufacturers - Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Strides Pharma Science Share Price Target For 2024
- 1.1.1: Strides Pharma Science Share Price Target Table For 2024
- 1.1.2: Short-Term Technical Outlook
- 1.2: Strides Pharma Science Share Price Target For 2025
- 1.2.1: Strides Pharma Science Share Price Target Table For 2025
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Strides Pharma Science Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
- 3: Strides Pharma Science Brief Company Overview
- 4: Strides Pharma Science Financial Performance
- 4.0.1: Is Strides Pharma Science A Good Buy For Long Term?
To predict the Strides Pharma Science's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Strides Pharma Science Share Price Target For 2024
The line chart displays the monthly closing prices of Strides Pharma Science with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Strides Pharma Science shares in 2024, see the table below.
Strides Pharma Science Share Price Target Table For 2024
| Level | Value | Analysis |
|---|---|---|
| 2024 Target 3 | 944.98 (+38.49%) | Price Action: Chart |
| 2024 Target 2 | 927.36 (+35.91%) | Price Action: Chart |
| 2024 Target 1 | 918.18 (+34.57%) | Fibonacci Extension Level 23.60% |
| Current Price | 682.30 | Strides Pharma Science's share price as of 20 Dec 2024 |
| Stop Loss 1 | 609.08 (-10.74%) | Price Action: May 2018 High |
| Stop Loss 2 | 600.47 (-12.00%) | Price Action: Oct 2014 High |
| Stop Loss 3 | 589.02 (-13.68%) | Price Action: Nov 2020 Low |
Short-Term Technical Outlook
Current Technical Position: Strides Pharma Science is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 25-day moving average at ₹1149.62 serves as the nearest technical reference point.
Historical Returns: 3-month: -51.14% | 6-month: -27.96% | 1-year: +5.29%
Strides Pharma Science Share Price Target For 2025
The line chart displays the monthly closing prices of Strides Pharma Science with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Strides Pharma Science shares in 2025, see the table below.
Strides Pharma Science Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 1451.0 (+112.66%) | Price Action: 12 Nov 2024 Low |
| 2025 Target 2 | 1434.0 (+110.17%) | Price Action: 14 Nov 2024 High |
| 2025 Target 1 | 1416.5 (+107.60%) | Price Action: 19 Nov 2024 High |
| Current Price | 682.30 | Strides Pharma Science's share price as of 20 Dec 2024 |
| Stop Loss 1 | 497.82 (-27.04%) | Fibonacci Retracement Level 98.60% |
| Stop Loss 2 | 492.84 (-27.77%) | Price Action: Chart |
| Stop Loss 3 | 483.97 (-29.07%) | Price Action: Chart |
Long-Term Technical Outlook
52-Week Range Analysis: Strides Pharma Science is currently trading near its 52-week low of ₹566.1, indicating potential value opportunity.
Long-Term Trend Analysis: The stock is in a bearish long-term trend, trading below key long-term moving averages.
Long-Term Performance: 1-year: +5.29% | 3-year: +53.43% | 5-year: +91.02%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Strides Pharma Science Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹682.30 | ||
| 2024 | ₹1,764.89 | +158.67% | ₹1,791.36 |
| 2025 | ₹2,846.97 | +61.31% | ₹2,889.67 |
| 2026 | ₹3,962.44 | +39.18% | ₹4,021.88 |
| 2027 | ₹4,888.04 | +23.36% | ₹4,961.36 |
| 2028 | ₹6,012.85 | +23.01% | ₹6,103.04 |
| 2029 | ₹7,481.04 | +24.42% | ₹7,593.26 |
| 2030 | ₹8,442.94 | +12.86% | ₹8,569.58 |
| 2031 | ₹9,553.14 | +13.15% | ₹9,696.44 |
| 2032 | ₹10,266.88 | +7.47% | ₹10,420.88 |
| 2033 | ₹11,435.92 | +11.39% | ₹11,768.15 |
| 2034 | ₹13,197.19 | +15.40% | ₹13,395.15 |
| 2035 | ₹14,038.91 | +6.38% | ₹14,249.49 |
| 2036 | ₹15,143.84 | +7.87% | ₹15,371.00 |
| 2037 | ₹15,645.72 | +3.31% | ₹16,055.26 |
| 2038 | ₹16,858.99 | +7.75% | ₹17,484.30 |
| 2039 | ₹18,895.51 | +12.08% | ₹19,178.94 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Strides Pharma Science Brief Company Overview
Strides Pharma Science Limited: A Global Pharmaceutical Powerhouse Strides Pharma Science Limited is a leading pharmaceutical company with a global presence. Established in 1990, the company has a vast product portfolio, including pharma generics, branded generics, and...
anti-infective drugs. With a strong focus on research and development, Strides Pharma Science offers innovative and affordable medicines to patients worldwide. As a renowned player in the pharmaceutical industry, the company has established strategic partnerships, such as the one with Orbicular Pharmaceutical Technologies Private Limited, to enhance its capabilities. Strides Pharma Science's commitment to quality and customer satisfaction has earned it a strong reputation among healthcare professionals and patients alike. Key Products and Services: Pharma generics, branded generics, anti-retrovirals, anti-malarials, anti-tuberculosis, Hepatitis drugs, and other infectious disease treatments. Market Presence: Africa, Australia, North America, Europe, Asia, India, and other international markets. Commitment: Providing affordable and accessible healthcare solutions to patients worldwide.Strides Pharma Science Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 8,018.81 Crore | Market valuation of Strides Pharma Science's shares. |
| Revenue (TTM) | 3,953.45 Crore | Total revenue generated by Strides Pharma Science over the past twelve months. |
| Net Income (TTM) | -1,524,790,016.00 | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +13.74% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | -2.49% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+20.00% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+19.69% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
140.18 | Company's total debt divided by total shareholder equity. |
| Total Debt | 2,794.65 Crore | Sum of Strides Pharma Science's current & long-term financial obligations. |
| Total Cash | 326.3 Crore | Total amount of liquid funds available to Strides Pharma Science. |
| Beta | 0.77 | Beta is less than 1 indicating that the Strides Pharma Science's price is less volatile than the market. |
Is Strides Pharma Science A Good Buy For Long Term?
Based on the provided data, Strides Pharma Science's recent performance is mixed. While revenue grew by 20% over the previous quarter, the company incurred a net loss of -152.47 Crore in the last 12 months. Its debt of 2,794.65 Crore is a concern, as is the negative profit margin of -2.49%. However, the company's past returns over various periods have been positive, indicating potential for long-term growth. Overall, considering both positive and negative factors, it can be considered an "average buy" for long-term investors who are willing to accept some risk.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
